7498 Results (Page 300 of 300)
Pharmaceuticals Markets Research Reports
Spain LASIK Surgery Market Analysis
Spain LASIK Surgery Market was valued at $68.13 Mn in 2023 and is predicted to grow at a CAGR of 4.21% from 2023 to 2030, to $ 90.93 Mn by 2030. The key drivers of this industry include the rising prevalence, growing disposable income, and increasing awareness. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
UK LASIK Surgery Market Analysis
UK LASIK Surgery Market was valued at $91.78 Mn in 2023 and is predicted to grow at a CAGR of 3.21% from 2023 to 2030, to $114.50 Mn by 2030. The key drivers of this industry include rising demand for vision corrections, increasing disposable income, and technological advancements. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Nidek Co. Ltd., and Carl ZEISS AG, among others.
China LASIK Surgery Market Analysis
China LASIK Surgery Market was valued at $283.77 Mn in 2023 and is predicted to grow at a CAGR of 6.71% from 2023 to 2030, to $447.09 Mn by 2030. The key drivers of this industry include the rising prevalence of myopia, growing disposable income, and technological advancements. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Indonesia LASIK Surgery Market Analysis
Indonesia LASIK Surgery Market was valued at $21.18 Mn in 2023 and is predicted to grow at a CAGR of 5.21% from 2023 to 2030, to $30.22 Mn by 2030. The key drivers of this industry include aging population and presbyopia, technological advancements, and the established ophthalmology market. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Japan LASIK Surgery Market Analysis
Japan LASIK Surgery Market was valued at $219.42 Mn in 2023 and is predicted to grow at a CAGR of 5.71% from 2023 to 2030, to $323.66 Mn by 2030. The key drivers of this industry include aging population and presbyopia, technological advancements, and established ophthalmology market. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Malaysia LASIK Surgery Market Analysis
Malaysia LASIK Surgery Market was valued at $5.68 Mn in 2023 and is predicted to grow at a CAGR of 5.41% from 2023 to 2030, to $8.21 Mn by 2030. The key drivers of this industry include the rising prevalence of vision problems, growing economy and disposable income, and medical tourism. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Singapore LASIK Surgery Market Analysis
Singapore LASIK Surgery Market was valued at $4.24 Mn in 2023 and is predicted to grow at a CAGR of 5.81% from 2023 to 2030, to $6.29 Mn by 2030. The key drivers of this industry include the rising affluent population, high prevalence of myopia, and technological advancements. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Philippines LASIK Surgery Market Analysis
Philippines LASIK Surgery Market was valued at $7.77 Mn in 2023 and is predicted to grow at a CAGR of 5.71% from 2023 to 2030, to $11.46 Mn by 2030. The key drivers of this industry include Market is therefore driven by significant factors like the rising prevalence of vision problems, growing economy, and expanding ophthalmology market. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Vietnam LASIK Surgery Market Analysis
Vietnam LASIK Surgery Market was valued at $17.65 Mn in 2023 and is predicted to grow at a CAGR of 5.44% from 2023 to 2030, to $25.57 Mn by 2030. The key drivers of this industry include increasing vision problems, economic growth and higher disposable income, and technological progress. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Nidek Co. Ltd, and Carl ZEISS AG, among others.
Egypt LASIK Surgery Market Analysis
Egypt LASIK Surgery Market was valued at $9.88 Mn in 2023 and is predicted to grow at a CAGR of 6.71% from 2023 to 2030, to $15.57 Mn by 2030. The key drivers of this industry include the rising prevalence of vision problems, growing middle class and disposable income, and increasing awareness and marketing. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
Kenya LASIK Surgery Market Analysis
Kenya LASIK Surgery Market was valued at $2.47 Mn in 2023 and is predicted to grow at a CAGR of 6.31% from 2023 to 2030, to $3.79 Mn by 2030. The key drivers of this industry include the rising prevalence of vision problems, the expanding middle class, and growing awareness and marketing. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
South Africa LASIK Surgery Market Analysis
South Africa LASIK Surgery Market was valued at $22.95 Mn in 2023 and is predicted to grow at a CAGR of 6.44% from 2023 to 2030, to $35.52 Mn by 2030. The key drivers of this industry include the rising prevalence of vision problems, growing disposable income, and technological advancements. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
India LASIK Surgery Market Analysis
India LASIK Surgery Market was valued at $64.20 Mn in 2023 and is predicted to grow at a CAGR of 8.21% from 2023 to 2030, to $111.53 Mn by 2030. The key drivers of this industry include the rising prevalence of vision problems, increasing insurance coverage, and technological advancements. The industry is primarily dominated by Johnson & Johnson Vision, Zeimer Ophthalmic System AG, Abbott, and Carl ZEISS AG, among others.
France Chronic Pain Therapeutics Market Analysis
The France Chronic Pain Therapeutics Market is anticipated to experience a growth from $2.043 Bn in 2022 to $2.996 Bn by 2030, with a CAGR of 4.9% during the forecast period of 2022-2030. The key drivers include increased public awareness and early diagnosis, unmet medical needs prompting demand for innovative solutions, and technological advancements contributing to a more comprehensive and accessible landscape. The France Chronic Pain Therapeutics Market encompasses various players across different segments, including Sanofi, Pfizer, Johnson & Johnson, Novartis, Bayer, AstraZeneca, Merck, GSK, Ipsen, Pierre Fabre, etc., among various others.
Malaysia Central Nervous System (CNS) Therapeutics Market Analysis
The Malaysia Central Nervous System (CNS)Therapeutics Market was valued at $338 Mn in 2022 and is predicted to grow at a CAGR of 6.6% from 2023 to 2030, to $563 Mn by 2030. The key drivers of this industry include the rising prevalence of CNS disorders, supportive government initiatives, and rising disposable income. The industry is primarily dominated by players such as Abbott, Novartis, Merck, Eisai, AstraZeneca, Otsuka, Duopharma, and Pharmaniaga among others.
Mexico Central Nervous System (CNS) Therapeutics Market Analysis
The Mexico Central Nervous System (CNS)Therapeutics Market was valued at $3.150 Bn in 2022 and is predicted to grow at a CAGR of 6.65% from 2023 to 2030, to $5.272 Bn by 2030. The key drivers of this industry include the rising burden of CNS disorders, increasing healthcare accessibility, and technological advancements. The industry is primarily dominated by players such as Pfizer, Sunovion, Biogen, Genomma, Eli Lilly, Teva, GSK, and Otsuka among others.
Philippines Central Nervous System (CNS) Therapeutics Market Analysis
The Philippines Central Nervous System (CNS)Therapeutics Market was valued at $462 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $788 Mn by 2030. The key drivers of this industry include the rising prevalence of CNS disorders, increasing healthcare infrastructure, and expanding pharmaceutical landscape. The industry is primarily dominated by players such as Abbott, Novartis, Merck, Eisai, AstraZeneca, United Laboratories, and CIG Philippines among others.
Saudi Arabia Central Nervous System (CNS) Therapeutics Market Analysis
The Saudi Arabia Central Nervous System (CNS)Therapeutics Market was valued at $3.570 Bn in 2022 and is predicted to grow at a CAGR of 7.9% from 2023 to 2030, to $6.559 Bn by 2030. The key drivers of this industry include the rising burden of CNS diseases, expanding healthcare spending, and technological advancements in the industry. The industry is primarily dominated by players such as Pfizer, Novartis, Hikma Pharmaceutical, Otsuka, AbbVie, and Eli Lilly among others.
Singapore Central Nervous System (CNS) Therapeutics Market Analysis
The Singapore Central Nervous System (CNS)Therapeutics Market was valued at $252 Mn in 2022 and is predicted to grow at a CAGR of 7% from 2023 to 2030, to $433 Mn by 2030. The key drivers of this industry include the increasing prevalence of CNS disorders, increasing government initiatives, and growing awareness and diagnoses. The industry is primarily dominated by players such as AbbVie, Novartis, Merck, AstraZeneca, Teva, and Eli Lilly among others.
South Africa Central Nervous System (CNS) Therapeutics Market Analysis
The South Africa Central Nervous System (CNS)Therapeutics Market was valued at $1.365 Bn in 2022 and is predicted to grow at a CAGR of 7.63% from 2023 to 2030, to $2.458 Bn by 2030. The key drivers of this industry include the increasing prevalence of CNS disorders, supportive government initiatives, and growing awareness. The industry is primarily dominated by players such as Novartis, Sanofi, AstraZeneca, Pfizer, and Roche among others.
Spain Graft-versus-Host Disease (GvHD) Therapeutics Market Analysis
The Spain GvHD Therapeutics Market was valued at $48.25 Mn in 2023 and is predicted to grow at a CAGR of 7.1% from 2023 to 2030, to $77.99 Mn by 2030. The growth in the Spanish market is driven by various factors like the rise in chronic GvHD cases, advanced technology, increasing awareness, government support, and the increasing prevalence of blood diseases. The major competitors in the market are Merck, Sanofi, Pfizer, Novartis, Mallinckrodt, Incyte, Abbott, and Takeda among others.
Spain Central Nervous System (CNS) Therapeutics Market Analysis
The Spain Central Nervous System (CNS)Therapeutics Market was valued at $4.053 Bn in 2022 and is predicted to grow at a CAGR of 5.4% from 2023 to 2030, to $6.173 Bn by 2030. The key drivers of this industry include the surge in the prevalence of CNS disorders, increased healthcare expenditure, and technological advancements in the industry. The industry is primarily dominated by players such as AbbVie, Pfizer, Eli Lilly, Grunenthal, Teva, Biogen, and Novartis among others.
UAE Graft-versus-Host Disease (GvHD) Therapeutics Market Analysis
The UAE GvHD Therapeutics Market was valued at $12.5 Mn in 2023 and is predicted to grow at a CAGR of 9.1% from 2023 to 2030, to $23 Mn by 2030. The drivers responsible for growth are the increasing prevalence of blood diseases, specialized treatments, and competitive landscapes. The key competitors are JCR, Takeda, Janssen, MaaT, XeniKos, Medac, Incyte, Mesoblast and others.